Miranda van Berkel

Dr. Miranda van Berkel

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
EKEmma J. Kooistra
Emma J. Kooistra
MBMiranda van Berkel
Miranda van Berkel
NKNoortje F. van Kempen
Noortje F. van Kempen
CLCeline R. M. van Latum
Celine R. M. van Latum
NBNiklas Bruse
Niklas Bruse
PPPeter Pickkers
Peter Pickkers
Background: Procalcitonin (PCT) and C-reactive protein (CRP) were previously shown to have value for the detection of secondary infections in critically ill COVID-19 patients. However, since the introduction of immunomodulatory therapy, the value of these biomarkers is unclear. We investigated PCT and CRP kinetics in critically ill COVID-19 patients treated with dexamethasone with or without tocilizumab, and assessed the value of these biomarkers to detect secondary bacterial infections.Methods: In this prospective study, 190 critically ill COVID-19 patients were divided into three treatment groups:no dexamethasone, no tocilizumab (D−T−),dexamethasone, no tocilizumab (D+T−), anddexamethasone and tocilizumab (D+T+). Serial data of PCT and CRP were aligned on the last day of dexamethasone treatment, and kinetics of these biomarkers were analyzed between 6 days prior to cessation of dexamethasone and 10 days afterwards. Furthermore, the D+T− and D+T+ groups were subdivided into secondary infection and no-secondary infection groups to analyze differences in PCT and CRP kinetics and calculate detection accuracy of these biomarkers for the occurrence of a secondary infection.Results: Following cessation of dexamethasone, there was a rebound in PCT and CRP levels, most pronounced in the D+T− group. Upon occurrence of a secondary infection, no significant increase in PCT and CRP levels was observed in the D+T− group (p = 0.052 andp = 0.08, respectively). Although PCT levels increased significantly in patients of the D+T+ group who developed a secondary infection (p = 0.0003), this rise was only apparent from day 2 post-infection onwards. CRP levels remained suppressed in the D+T+ group. Receiver operating curve analysis of PCT and CRP levels yielded area under the curves of 0.52 and 0.55, respectively, which are both markedly lower than those found in the group of COVID-19 patients not treated with immunomodulatory drugs (0.80 and 0.76, respectively, withpvalues for differences between groups of 0.001 and 0.02, respectively).Conclusions: Cessation of dexamethasone in critically ill COVID-19 patients results in a rebound increase in PCT and CRP levels unrelated to the occurrence of secondary bacterial infections. Furthermore, immunomodulatory treatment with dexamethasone and tocilizumabconsiderably reducesthe value of PCT and CRP for detection of secondary infections in COVID-19 patients.

5 March 2024 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
PDF file
CHChrsitian Hulzebos
Chrsitian Hulzebos
JCJohanna E. Camara
Johanna E. Camara
MBMiranda van Berkel
Miranda van Berkel
VDVincent Delatour
Vincent Delatour
SLStanley F. Lo
Stanley F. Lo
OBOn behalf of the IFCC Working Group Neonatal Bilirubin
On behalf of the IFCC Working Group Neonatal Bilirubin
Measurement of total bilirubin (TBil) concentration in serum is the gold standard approach for diagnosing neonatal unconjugated hyperbilirubinemia. It is of utmost importance that the measured TBil concentration is sufficiently accurate to prevent under treatment, unnecessary escalation of care, or overtreatment. However, it is widely recognized that TBil measurements urgently require improvement in neonatal clinical chemistry. External quality assessment (EQA) programs for TBil assess for differences between laboratories and provide supporting evidence of significant differences between various methods, manufacturers and measurement platforms. At the same time, many countries have adopted or only slightly adapted the neonatal hyperbilirubinemia management guidelines from the USA or UK, often without addressing differences in the methodology of TBil measurements. In this report, we provide an overview of the components of bilirubin that are measured by laboratory platforms, the availability of current reference measurement procedures and reference materials, and the role of EQA surveys in this context. Furthermore, the current status of agreement in neonatal bilirubin against clinical decision thresholds is reviewed. We advocate for enhancements in accuracy and comparability of neonatal TBil measurements, propose a path forward to accomplish this, and reflect on the position of the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Working Group Neonatal Bilirubin (WG-NB) in this matter.

23 January 2026 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Open access
MLMarith van Schrojenstein Lantman
Marith van Schrojenstein Lantman
CCChrista Cobbaert
Christa Cobbaert
MPMauro Panteghini
Mauro Panteghini
MBMiranda van Berkel
Miranda van Berkel
RSRuben Smeets
Ruben Smeets
MTMarc H M Thelen
Marc H M Thelen
Application of the results provided by medical laboratories plays an essential role in medical decision-making. This is not limited to diagnosis and monitoring of disease but also involves its use in other phases of the health continuum, e.g., predisposition, risk stratification, screening, staging, prognosis, and surveillance. With the growing importance of precision medicine, the importance of requirements related to clinical performance, and consequently analytical performance of laboratory tests, also grows. To allow the community of laboratory medicine to translate clinical need into a test arsenal with adequate performance, the application of metrology concepts is essential. This paper summarizes, for all steps in the examination process from test development to clinical interpretation, why and how metrological traceability is a fundamental requirement for adequate medical decision-making and is critical for correct use of test results in algorithms and artificial intelligence-led approaches. This includes the importance of metrology concepts and their correct implementation for obtaining equivalence of test results upon cross-facility result exchange for primary or secondary use in healthcare and research. This is not limited to biochemistry and hematology but is also of importance to other areas of laboratory medicine, including microbiology. This paper provides an overview of the purposes of the underappreciated science of metrology in modern laboratory medicine and its importance to patients and caregivers.

Verified
Journal Article
Open access
PDF file
DLDennis Lindqvist
Dennis Lindqvist
MHMagnus Hansson
Magnus Hansson
MTMercy Thomas
Mercy Thomas
CHChrsitian Hulzebos
Chrsitian Hulzebos
Libor VitekLibor Vitek
Libor Vitek
MBMiranda van Berkel
Miranda van Berkel
Phototherapy is the standard treatment for neonatal hyperbilirubinemia. During phototherapy, the highly lipophilic bilirubin is converted into more hydrophilic photoisomers, which can be more easily excreted from the body. This process typically lowers bilirubin levels to non-harmful concentrations. However, despite decades of research into the formation and role of bilirubin photoisomers, methodological limitations and the compound’s complex biochemistry have hindered comprehensive understanding. This review provides an updated overview of current knowledge on bilirubin photoisomers, including their basic chemistry, analytical quantification, clinical relevance, and future research directions. Improved insight into the mechanism of photoisomer formation and kinetics may inform optimization of phototherapy parameters, including light intensity and wavelength, and offer additional indicators of treatment efficacy beyond total bilirubin concentration. Advances in sensitive and standardized mass spectrometry techniques now enable more accurate measurement of different bilirubin isomers and serve as a first step towards a deeper insight into the clinical relevance of photoisomers.

30 December 2025 in Clinical Chemistry
Verified
Journal Article
Open access
LWLauren E H Westenberg
Lauren E H Westenberg
MLMarith van Schrojenstein Lantman
Marith van Schrojenstein Lantman
MBMiranda van Berkel
Miranda van Berkel
MTMarc H M Thelen
Marc H M Thelen
ATAndrei Tintu
Andrei Tintu
CHChrsitian Hulzebos
Chrsitian Hulzebos
Background: Accurate quantification of neonatal bilirubin remains a perennial challenge. To monitor analytical performance of total bilirubin measurements across hospitals in the Netherlands, a dedicated neonatal external quality assessment (EQA) program is in place. Methods: We retrospectively analyzed Dutch EQA data from 2013 until 2025. Each year, the 81 participating laboratories received 24 pooled adult blood serum samples spiked with unconjugated bilirubin (range 100–400 µmol/L or 5.85–23.40 mg/dL). Bias from the target value determined by the reference measurement procedure (RMP) and the coefficient of variation (CV) were established for both unfactored and factored measurements. Results: In total, 25 983 bilirubin measurements were analyzed. Three analytical principles were used on 12 platforms from 6 manufacturers. Diazo-based methods exhibited the lowest median bias (+0.4% in 2024), alongside spectrophotometric methods (−3.8% in 2024). Vanadate-based methods showed a bias of +19.5% in 2024 that was reduced to +3.0% for factored measurements. Substantial differences in bias were observed among manufacturers and platforms, with some exhibiting concentration dependency. Comparable patterns were seen for CVs, which generally remained below 5%. Conclusion: EQA results demonstrated temporal variability in bias across all analytical principles, manufacturers, and platforms used for neonatal bilirubin assays. Bias was found to vary with bilirubin concentration. Standardization of neonatal bilirubin assays is urgently needed to ensure more reliable and accurate measurements across different systems. Meanwhile, EQA programs are important in monitoring future assay adjustments to ensure appropriate and consistent management of neonatal hyperbilirubinemia.

24 January 2025 in Clinical Nutrition ESPEN
Verified
Journal Article
Open access
MBMiranda van Berkel
Miranda van Berkel
JBJudith Beurskens-Meijerink
Judith Beurskens-Meijerink
NBNicole Buters-Ambrosius
Nicole Buters-Ambrosius
EHEline Van Der Hagen
Eline Van Der Hagen
GWGetty G. J. Huisman-de Waal
Getty G. J. Huisman-de Waal
GWGeert Wanten
Geert Wanten
Measurement of the urine sodium concentration (USC) is a simple procedure that in many patients adequately indicates their hydration status. This is of particular importance in patients suffering from short bowel syndrome (SBS), who may very rapidly dehydrate and are at risk for permanently compromising their kidney function. A point of care testing (POCT) that allows reliable measurement of USC would enable these patients to effectively evaluate their sodium- and water balance in the at home setting, thereby avoiding hospital visits and delayed test results. In this study, a POCT device to assess USC was first analytically validated after which it was applied for the at home evaluation of the hydration status in patients with SBS. First, we validated the imprecision, bias and limit of quantification of USC as measured with the Fisic Medimate POCT device in comparison to an automated routine chemistry system. Next, the device was used for monitoring USC at home in 21 patients with SBS, including an evaluation of user friendliness System Usability Scale (SUS) and accuracy for detecting low sodium levels as compared to the routine chemistry system. The imprecision of the POCT device at low USC was 6.1 %. In samples at the clinical decision threshold to identify patients at the verge of dehydration of 20 mmol/l as measured by routine chemistry USC, the POCT device demonstrated a mean estimation of USC of 20.6 mmol/l (95 % CI 18.8-22.4). Dehydration was detected with a sensitivity of 95 % when the medical decision limit for urinary sodium on the POCT device was set at a safe concentration of 30 mmol/l. Using the device was straightforward and easy to learn for patients with an overall System Usability Scale (SUS) score of 86. USC measurements using this POCT device can be safely integrated into daily practice for early detection of dehydration in patients with SBS. Clear patient instructions to ensure accurate drop dispensing and a higher clinical decision threshold of USC of 30 mmol/l will allow a high sensitivity for detecting dehydration in patients with short bowel syndrome.